Iovance Biotherapeutics

Yahoo Finance • 8 days ago

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltratin... Full story

Yahoo Finance • 24 days ago

Iovance Biotherapeutics reports mixed Q3 results; reaffirms FY25 outlook

* Iovance Biotherapeutics press release [https://seekingalpha.com/pr/20296680-iovance-biotherapeutics-highlights-business-achievements-pipeline-milestones-and-third] (IOVA [https://seekingalpha.com/symbol/IOVA]): Q3 GAAP EPS of -$0.25 be... Full story

Yahoo Finance • last month

IOVANCE INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Long-Term Iovance, Inc. Stockholders

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Iovance (IOVA) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in Iovance between May 9, 2024 an... Full story

Yahoo Finance • 2 months ago

Is Iovance Biotherapeutics Stock Your Ticket to Becoming a Millionaire?

Key Points Iovance Biotherapeutics was the first drug developer to win FDA approval of an immune cell/T-cell therapy. The underlying science, however, may offer more long-term potential than the single drug in question. This stock’s treme... Full story

Yahoo Finance • 2 months ago

IOVANCE (IOVA) ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Iovance Biotherapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Iovance (IOVA) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in Iovance between May 9, 2024 an... Full story

Yahoo Finance • 2 months ago

Shares of WOR Now Oversold

In trading on Wednesday, shares of Worthington Enterprises Inc (Symbol: WOR) entered into oversold territory, changing hands as low as $50.55 per share. We define oversold territory using the Relative Strength Index, or RSI, which is a te... Full story

Yahoo Finance • 2 months ago

Can This Beaten-Down Stock Bounce Back?

Key Points Iovance Biotherapeutics' cancer therapy, Amtagvi, is experiencing decent sales growth. However, the biotech faces some challenges that will make it difficult to turn a profit. Though there could be some catalysts on the way, Io... Full story

Yahoo Finance • 2 months ago

Advancing Cancer Research Brings New Hope for Patients Worldwide

NetworkNewsWire Editorial Coverage NEW YORK, Sept. 17, 2025 /PRNewswire/ -- Progress in RNA-based medicines, immunotherapies and targeted treatments is not simply desirable, it is a critical necessity. Deadly cancers such as glioblastoma... Full story

Yahoo Finance • 3 months ago

Iovance Biotherapeutics to Present at Upcoming Conferences

SAN CARLOS, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies... Full story

Yahoo Finance • 3 months ago

Biggest stock movers Tuesday: PANW, BLNK, and more

[financial graph on technology abstract background] monsitj Stock futures edged lower in Tuesday’s premarket trading after a subdued start to a pivotal week marked by key Federal Reserve speeches, major retail earnings, and investor cauti... Full story

Yahoo Finance • 3 months ago

Iovance gets conditional Health Canada approval for Amtagvi

[Cancer Outbreak] wildpixel/iStock via Getty Images Iovance Biotherapeutics (NASDAQ:IOVA [https://seekingalpha.com/symbol/IOVA]) shares rose post market after it received Health Canada approval with conditions for its T-cell immunotherapy... Full story

Yahoo Finance • 3 months ago

Curious about the stocks that are showing activity after the closing bell on Monday?

The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today. [postmarket] AFTER HOURS GAINERS TICKER CHANGE COMMENT LASE [https://www.chartmill.com/stock/q... Full story

Yahoo Finance • 3 months ago

Iovance’s Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma

First T cell therapy for a solid tumor cancer and first treatment option approved in Canada for advanced melanoma after anti-PD-1 and targeted therapy SAN CARLOS, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (... Full story

Yahoo Finance • 4 months ago

Iovance Biotherapeutics’ SWOT analysis: navigating challenges in cancer immunotherapy stock

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company with a market capitalization of $890 million specializing in novel cancer immunotherapies, finds itself at a critical juncture as it navigates the complex landscape of on... Full story

Yahoo Finance • 4 months ago

Replimune Group’s SWOT analysis: oncology biotech stock faces FDA hurdles

Replimune Group Inc (NASDAQ:REPL), a biotechnology company focused on developing novel oncolytic immunotherapies for cancer treatment, has been navigating a complex landscape of clinical trials, regulatory challenges, and market expectatio... Full story

Yahoo Finance • 4 months ago

Which stocks are moving before the opening bell on Friday?

Before the opening bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. [premarket] TODAY'S PRE-MARKET GAINERS TICKER CHANGE COMMENT ORIS [https://www.ch... Full story

Yahoo Finance • 4 months ago

Curious about the stocks that are showing activity after the closing bell on Thursday?

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. [postmarket] GAINERS TICKER CHANGE COMMENT MRM [https://www.chartmill.com/stock/quote/MRM/profile] 56.67% ME... Full story

Yahoo Finance • 4 months ago

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025

$60.0M in 2Q25 Total Product Revenue More than 100 Patients Treated with Amtagvi® in 2Q25 Strategic Restructuring Extends Cash Runway into 4Q26 FY25 Total Product Revenue Guidance of $250M-$300M Reiterated SAN CARLOS, Calif., Aug. 07,... Full story

Yahoo Finance • 4 months ago

Iovance Biotherapeutics' SWOT analysis: stock faces challenges amid promising data

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company specializing in novel cancer immunotherapies, finds itself at a critical juncture as it navigates the complexities of commercializing its lead product, Amtagvi, while fac... Full story

Yahoo Finance • 4 months ago

Replimune's SWOT analysis: biotech stock faces FDA setback, industry remains positive

Replimune Group Inc (NASDAQ:REPL), a biotechnology company focused on developing oncolytic immunotherapies for cancer treatment, has recently experienced a significant setback in its regulatory journey. Trading at $3.17, the stock has dec... Full story